Videos
A Case of HR+ Metastatic Breast Cancer
JAK Inhibition for the Management of Primary Myelofibrosis
Primary Myelofibrosis
CLL Case Review: IgHV-Unmutated Therapy Options
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma
2
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
3
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
4
FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma
5